August 28, 2025 a 01:01 pm
COR: Analysts Ratings - Cencora, Inc.
Cencora, Inc., previously known as AmerisourceBergen Corporation, is a prominent player in the pharmaceutical distribution industry. Given its broad range of services and products within the healthcare sector, the company has maintained considerable interest from analysts. The recent name change to Cencora signals a strategic rebranding effort, potentially aligning with new market opportunities.
Historical Stock Grades
The latest analyst ratings for August 2025 reveal a predominance of 'Buy' recommendations, reflecting optimism towards Cencora’s business strategies and performance.
| Rating Category | Number of Recommendations | Score |
|---|---|---|
| Strong Buy | 1 | |
| Buy | 10 | |
| Hold | 5 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
Over the past year, analyst sentiment towards Cencora shows a stable count of 'Buy' recommendations, with 'Hold' and 'Sell' categories relatively unchanged.
- The count of 'Strong Buy' ratings decreased from 5 in 2024 to 1 in 2025.
- 'Buy' recommendations have remained consistent, becoming the dominant sentiment.
- 'Hold' ratings show minor fluctuations but overall stability.
- 'Strong Sell' recommendations remain minimal, indicating limited bearish sentiment.
Percentage Trends
The percentage distribution highlights a cautious yet positive outlook with a significant proportion of 'Buy' ratings.
- There is a visible shift from 'Strong Buy' towards 'Buy', suggesting moderated confidence.
- Approximately 67% of the ratings for August 2025 are 'Buy', reflecting favorable market conditions.
- 'Hold' ratings represent around 33%, maintaining a balanced perspective.
- The consistent 'Strong Sell' rating underscores some lack of confidence from a minority of analysts.
Latest Analyst Recommendations
Recent analyst actions demonstrate a maintained strategic stance towards Cencora's market performance.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-13 | Overweight | Overweight | Wells Fargo |
| 2025-07-16 | Equal Weight | Equal Weight | Morgan Stanley |
| 2025-06-30 | Hold | Hold | Jefferies |
| 2025-06-03 | Overweight | Equal Weight | Wells Fargo |
| 2025-05-08 | Buy | Buy | Citigroup |
Analyst Recommendations with Change of Opinion
Changes in recommendation reveal strategic repositioning by some analysts.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-06-03 | Overweight | Equal Weight | Wells Fargo |
| 2022-10-11 | Buy | Neutral | B of A Securities |
| 2022-10-10 | Buy | Neutral | B of A Securities |
| 2022-07-11 | In Line | Outperform | Evercore ISI Group |
| 2022-07-10 | In Line | Outperform | Evercore ISI Group |
Interpretation
The overall market sentiment towards Cencora suggests cautious optimism. The predominance of 'Buy' recommendations highlights confidence in the company's strategic initiatives and market positioning. While 'Strong Buy' ratings have declined, indicating tempered enthusiasm, the consistency in 'Buy' and 'Hold' ratings reflects stability. Minor shifts in analyst opinions suggest reassessment of market dynamics, but no major downturn in sentiment is evident. This stable outlook, combined with strategic upgrades, bodes well for continued market trust, albeit with some reservations.
Conclusion
In summary, Cencora, Inc. remains a solid investment candidate with a strong footing within the pharmaceutical distribution sector. The consistent 'Buy' consensus, despite reduced 'Strong Buy' sentiment, emphasizes potential growth opportunities and strategic robustness. Investors should note the stability in ratings and modest opinion shifts as they navigate potential risks. Long-term growth prospects appear favorable due to the company's expansive service offering and strategic rebranding efforts. Nonetheless, market volatility and sector dynamics warrant careful monitoring.